Ron kinase transphosphorylation sustains MET oncogene addiction.

Receptors for the scatter factors HGF and MSP that are encoded by the MET and RON oncogenes are key players in invasive growth. Receptor cross-talk between Met and Ron occurs. Amplification of the MET oncogene results in kinase activation, deregulated expression of an invasive growth phenotype, and addiction to MET oncogene signaling (i.e., dependency on sustained Met signaling for survival and proliferation). Here we show that cancer cells addicted to MET also display constitutive activation of the Ron kinase. In human cancer cell lines coexpressing the 2 oncogenes, Ron is specifically transphosphorylated by activated Met. In contrast, Ron phosphorylation is not triggered in cells harboring constitutively active kinase receptors other than Met, including Egfr or Her2. Furthermore, Ron phosphorylation is suppressed by Met-specific kinase inhibitors (PHA-665752 or JNJ-38877605). Last, Ron phosphorylation is quenched by reducing cell surface expression of Met proteins by antibody-induced shedding. In MET-addicted cancer cells, short hairpin RNA-mediated silencing of RON expression resulted in decreased proliferation and clonogenic activity in vitro and tumorigenicity in vivo. Our findings establish that oncogene addiction to MET involves Ron transactivation, pointing to Ron kinase as a target for combinatorial cancer therapy.

[1]  D. Haber,et al.  Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents , 2010, Nature Reviews Cancer.

[2]  M. Sliwkowski,et al.  Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. , 2009, Cancer cell.

[3]  A. Iafrate,et al.  Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. , 2009, Cancer research.

[4]  P. Comoglio,et al.  Silencing the MET oncogene leads to regression of experimental tumors and metastases , 2008, Oncogene.

[5]  A. Iafrate,et al.  Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling , 2007, Proceedings of the National Academy of Sciences.

[6]  P. Comoglio,et al.  The MET receptor tyrosine kinase in invasion and metastasis , 2007, Journal of cellular physiology.

[7]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[8]  D. Tuveson,et al.  The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. , 2007, Cancer research.

[9]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[10]  N. Kohl,et al.  Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. , 2007, Cancer research.

[11]  M. Collins,et al.  Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. , 2006, Cancer research.

[12]  Yuan Cheng,et al.  Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. , 2006, Cancer research.

[13]  C. Scuoppo,et al.  Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. , 2006, Cancer research.

[14]  P. Circosta,et al.  Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Gayatry Mohapatra,et al.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K K Jain,et al.  Personalised medicine for cancer: from drug development into clinical practice , 2005, Expert opinion on pharmacotherapy.

[17]  T. Tzai,et al.  Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder , 2005, British Journal of Cancer.

[18]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[19]  L. Ellis,et al.  RON, a Tyrosine Kinase Receptor Involved in Tumor Progression and Metastasis , 2005, Annals of Surgical Oncology.

[20]  M. Collins,et al.  Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. , 2005, Cancer research.

[21]  M. Collins,et al.  Ron tyrosine kinase receptor regulates papilloma growth and malignant conversion in a murine model of skin carcinogenesis , 2005, Oncogene.

[22]  Ming-Hai Wang,et al.  RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells , 2004, Oncogene.

[23]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[24]  L. Naldini,et al.  Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. , 2004, Cancer cell.

[25]  M. Lerman,et al.  The Soluble Sema Domain of the RON Receptor Inhibits Macrophage-stimulating Protein-induced Receptor Activation* , 2004, Journal of Biological Chemistry.

[26]  J. Christensen,et al.  A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. , 2003, Cancer research.

[27]  D. Katsaros,et al.  The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. , 2003, Experimental cell research.

[28]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. Collesi,et al.  The Ron Proto-oncogene Product Is a Phenotypic Marker of Renal Oncocytoma , 2003, The American journal of surgical pathology.

[30]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[31]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[32]  Ming-Hai Wang,et al.  Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo , 2002, Oncogene.

[33]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[34]  L. Trusolino,et al.  Scatter-factor and semaphorin receptors: cell signalling for invasive growth , 2002, Nature Reviews Cancer.

[35]  T. Suda,et al.  Immunohistochemical Analysis of Distribution of RON Receptor Tyrosine Kinase in Human Digestive Organs , 2001, Digestive Diseases and Sciences.

[36]  M. H. Wang,et al.  Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. , 2000, Experimental cell research.

[37]  L. Naldini,et al.  Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy , 2000, The journal of gene medicine.

[38]  M. Stella,et al.  Cross-talk between the proto-oncogenes Met and Ron , 2000, Oncogene.

[39]  D. Witte,et al.  The Ron/STK receptor tyrosine kinase is essential for peri-implantation development in the mouse. , 1999, The Journal of clinical investigation.

[40]  P. Sismondi,et al.  Overexpression of the RON gene in human breast carcinoma , 1998, Oncogene.

[41]  D. Sugarbaker,et al.  Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: induction of receptor tyrosine phosphorylation and cell migration. , 1998, American journal of respiratory cell and molecular biology.

[42]  D. Seol,et al.  Co‐expression and regulation of Met and Ron proto‐oncogenes in human hepatocellular carcinoma tissues and cell lines , 1997, Hepatology.

[43]  P. Comoglio,et al.  Constitutive activation of the RON gene promotes invasive growth but not transformation , 1996, Molecular and cellular biology.

[44]  K. Matsumoto,et al.  Cloning and expression of Xenopus HGF-like protein (HLP) and Ron/HLP receptor implicate their involvement in early neural development. , 1996, Biochemical and biophysical research communications.

[45]  L. Naldini,et al.  RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. , 1994, The EMBO journal.

[46]  M. Grooteclaes,et al.  Expression of the c-erbB2 gene in the BT474 human mammary tumor cell line: measurement of c-erbB2 mRNA half-life. , 1993, Oncogene.

[47]  P. Comoglio,et al.  C-terminal truncated forms of Met, the hepatocyte growth factor receptor , 1991, Molecular and cellular biology.

[48]  B. Boman,et al.  Extrachromosomal amplification of the epidermal growth factor receptor gene in a human colon carcinoma cell line , 1991, Genes, chromosomes & cancer.

[49]  P. Comoglio,et al.  p145, a protein with associated tyrosine kinase activity in a human gastric carcinoma cell line , 1988, Molecular and cellular biology.

[50]  L. Trusolino,et al.  Only a subset of Met-activated pathways are required to sustain oncogene addiction. , 2009, Science signaling.

[51]  F. Maurer,et al.  The ErbB 2 ErbB 3 heterodimer functions as an oncogenic unit : ErbB 2 requires ErbB 3 to drive breast tumor cell proliferation , 2003, Nature Reviews Cancer.